

Supplementary Material

Supplementary Table 1. Definitions of comorbidities and medication classes during look-back and follow-up period.....	2
Supplementary Table 2. Socio-demographic characteristics by availability of follow-up information (n = 388,060).....	5
Supplementary Table 3. Socio-demographic, clinical and community characteristics of exposure cohorts after weighting	7
Supplementary Table 4. Changes during follow-up period in body mass index	9
Supplementary Table 5. Modeled marginal estimates of changes in body mass index during follow-up by exposure cohort	10
Supplementary Table 6. Modeled marginal estimates of changes in body mass index during follow-up by exposure cohort among those with 100 days of follow-up and at least two BMI encounters, n = 1,103,882 observations from 124,934 patients	12
Supplementary Table 7. Modeled marginal estimates of changes in body mass index during follow-up by exposure cohort after adjusting for number and type of encounters between BMI measurements, n = 1,230,631 observations from 194,792 patients	14
Supplementary Table 8. Modeled marginal estimates of changes in body mass index during follow-up by exposure cohort after adjusting for COVID-19 cases and test positivity rate, n = 1,230,631 observations from 194,792 patients	16
Supplementary Table 9. Modeled marginal estimates of changes in body mass index during follow-up by exposure cohort after adjusting for laboratory parameters with multiple imputation, n = 1,230,631 observations from 194,792 patients	18
Supplementary Figure 1. Cohort selection.....	20
Supplementary Figure 2. Flowchart of analytic sample selection	21
Supplementary Figure 3. Statistical analysis approach.....	22
Supplementary Methods. Detailed statistical methods	23

Supplementary Table 1. Definitions of comorbidities and medication classes during look-back and follow-up period

Exposure Definition	Codes included
COVID-19 Lab	94500-6,94309-2,94558-4,94534-5,94759-8,95209-3,95608-6,95380-2,94316-7,95422-2,94533-7,94565-9,94756-4,94642-6,94306-8,95406-5,95425-5,87635
COVID-19 ICD10-CM	U07.1, U07.2, J12.81, J12.82, B34.2, B97.2, B97.21, B97.29, U04, U04.9
Data for Diabetes Diagnosis (Weise 2018)	
HbA1c	4548-4, 41995-2, 55454-3, 71875-9, 549-2, 17856-6, 59261-6, 62388-4, 17855-8
Diabetes	E11.00, E11.01, E11.21, E11.22, E11.29, E11.311, E11.319, E11.321, E11.329, E11.331, E11.339, E11.341, E11.349, E11.351, E11.359, E11.36, E11.39, E11.40, E11.41, E11.42, E11.43, E11.44, E11.49, E11.51, E11.52, E11.59, E11.610, E11.618, E11.620, E11.621, E11.622, E11.628, E11.630, E11.638, E11.641, E11.649, E11.65, E11.69, E11.8, E11.9
Sulfonylurea	tolazamide [Tolinase]; acetohexamide [Dymelor]; tolbutamide [Orinase, Orinase Diagnostic, Tol-Tab], chlorpropamide [Diabinese] [diabanase][diabinase]; glipizide [Glucotrol, Glucotrol XL, Glucatorl]; glyburide [Micronase, Glynase, Diabetamide, Diabeta]; glimepiride [Amaryl]
Biguanide	metformin [Glucophage]
Meglitinide	repaglinide [Prandin]; nateglinide [Starlix]
Alpha glucosidase Inhibitor	miglitol [Glyset]; acarbose [Precose]
Thiazolidinedione	rosiglitazone [Avandia]; pioglitazone [ACTOS]; troglitazone [Rezulin]
Sodium-glucose cotransporter-2 Inhibitor	dapagliflozin [Farxiga]; canagliflozin [Invokana or Sulisent]; empagliflozin [Jardiance], ertugliflozin [Segluromet or Steglatro or Steglujan]
Dipeptidyl peptidase-4 Inhibitors	sitagliptin [Januvia]; saxagliptin [Onglyza]; linagliptin [Tradjenta], alogliptin [Kazano or Nesina or Oseni]
Glucose-dependent insulintropic peptide-1	exenatide [Byetta]; liraglutide [Victoza], lixisenatide [Adlyxin or Soliqua], semaglutide [Rybelsus or Ozempic or Wegovy]

Insulin	regular insulin [Humulin R, Novolin R]; insulin lispro [Humalog]; insulin aspart [Novolog]; insulin glulisine [Apidra]; prompt insulin zinc [Semilente]; isophane insulin, neutral protamine hagedorn [NPH] [Humulin N, Novolin N]; insulin zinc [Lente]; extended insulin zinc insulin [Ultralente]; insulin glargine [Lantus]; insulin detemir [Levemir]
Comorbidities (Bachmann 2020)	
Cerebrovascular – Transient Ischemic Attack	G45.0; G45.1; G45.8; G45.9; I67.848
Cerebrovascular – Stroke	I67.89; I60.9; I61.9; I63.30; I63.40; I63.50; I66.09; I66.19; I66.29; I66.9; I67.89
Cardiovascular – Atrial Fibrillation	I48.91; I48.92
Cardiovascular – Arrhythmia	I44.*; I45.*; I47.*; I49.*
Cardiovascular – Coronary Artery Disease	I24.*; I25.*; I20.*
Cardiovascular – Congestive Heart Failure	I11.0; I13.0; I13.2; I50.9; I50.1; I50.20; I50.21; I50.22; I50.23; I50.30; I50.31; I50.32; I50.33; I50.40; I50.41; I50.42; I50.43
Cardiovascular – Cardiac valve disease	I05.*; I06.*; I08.*; I34.*; I35.*
Cardiovascular – Peripheral artery disease, revascularization, peripheral vasodilators	I70.2*; I72.*; I77.*; I73.9; I75.*
Hypertension	I10; I11.*; I12.*; I13.*
Pulmonary – General	J96.*; R092; I26.9*; I27.*
Pulmonary – COPD/ Emphysema/Asthma	J41.0; J41.1; J44.9; J44.1; J44.0; J41.8; J42; J43; J43.0; J43.1; J43.2; J43.8; J43.9; J45.20; J45.22; J45.21; J45.990; J45.991; J45.909; J45.998; J45.902; J45.901; Z13.83
Lipid disorders	E78.*
Obesity	E66.0; E66.1; E66.2; E66.8; E66.9
Labs	
LDL	13457-7, 18262-6, 2089-1, 11054-4
HDL	18263-4, 2085-9
Triglycerides	12951-0, 2571-8
ALT	1742-6, 1744-2
AST	1920-8

HbA1c	4548-4, 41995-2, 55454-3, 71875-9, 549-2, 17856-6, 59261-6, 62388-4, 17855-8
Serum Creatinine	2160-0
Glucose	2345-7, 2339-0, 41653-7, 2340-8, 27353-2, 1547-9, 1558-6
Encounters	Types of encounters included clinical (ambulatory, inpatient, observation stay, emergency department, emergency to inpatient, institutional professional consult, non-acute institutional stay, telehealth), laboratory (other ambulatory, unknown, no information, and other encounters and matched to lab result) and pharmacy (other ambulatory, unknown, no information, and other encounters matched to prescription data) visits.

Supplementary Table 2. Socio-demographic characteristics by availability of follow-up information (n = 388,060)

				Lookback available	
	Overall	Lookback available	Lookback not available	Available during both lookback and follow-up	Only lookback
<i>N</i>	388,060	249,743	138,317	194,792	54,951
Exposure Group					
Exposed	74,629 (19%)	44,436 (18%)	30,193 (22%)	32,384 (17%)	12,052 (22%)
Unexposed	238,499 (61%)	164,118 (66%)	74,381 (54%)	127,142 (65%)	36,976 (67%)
Historical	74,932 (19%)	41,189 (16%)	33,743 (24%)	35,266 (18%)	5,923 (11%)
Female (%)	241,787 (62%)	155,223 (62%)	86,564 (63%)	120,709 (62%)	34,514 (63%)
Age (years)	51.0 (19.2)	51.9 (18.9)	49.2 (19.6)	52.1 (18.6)	51.4 (19.8)
Race/ethnicity					
NH White	195,734 (50.4%)	128,613 (51.5%)	67,121 (48.5%)	101,352 (52.0%)	27,261 (49.6%)
NH Black	78,115 (20.1%)	53,702 (21.5%)	24,413 (17.7%)	43,169 (22.2%)	10,533 (19.2%)
Hispanic	87,189 (22.5%)	53,354 (21.4%)	33,835 (24.5%)	40,025 (20.5%)	13,329 (24.3%)
NH Other	25,617 (6.6%)	14,023 (5.6%)	11,594 (8.4%)	10,221 (5.2%)	3,802 (6.9%)
Smoking					
Yes	124,816 (44%)	117,593 (47%)	7,223 (23%)	103,185 (53%)	14,408 (26%)
Missing	106,447	0	106,447		
Health System					
Source 1	105,379 (31%)	92,403 (42%)	12,976 (11%)	84,682 (49%)	7,721 (17%)
Source 2	77,730 (23%)	51,650 (24%)	26,080 (21%)	39,459 (23%)	12,191 (26%)
Source 3	47,066 (14%)	24,524 (11%)	22,542 (19%)	14,521 (8.5%)	10,003 (22%)
Source 4	41,752 (12%)	19,041 (8.7%)	22,711 (19%)	12,780 (7.5%)	6,261 (14%)
Source 5	15,605 (4.6%)	12,263 (5.6%)	3,342 (2.7%)	9,442 (5.5%)	2,821 (6.1%)
Source 6	1,428 (0.4%)	988 (0.5%)	440 (0.4%)	794 (0.5%)	194 (0.4%)
Source 7	50,483 (15%)	16,775 (7.7%)	33,708 (28%)	9,722 (5.7%)	7,053 (15%)
Missing	48,617	32,099	16,518	23,392	8,707
Primary Insurance					
Medicare	52,058 (15%)	38,768 (18%)	13,290 (11%)	32,680 (19%)	6,088 (13%)
Medicaid	23,333 (6.9%)	18,154 (8.3%)	5,179 (4.3%)	15,901 (9.3%)	2,253 (4.9%)
Other Government	7,838 (2.3%)	5,299 (2.4%)	2,539 (2.1%)	4,417 (2.6%)	882 (1.9%)
Private		99,648 (46%)		78,890 (46%)	20,758 (45%)
No Insurance	7,408 (2.2%)	4,210 (1.9%)	3,198 (2.6%)	3,248 (1.9%)	962 (2.1%)
No Information	98,498 (29%)	51,565 (24%)	46,933 (39%)	36,264 (21%)	15,301 (33%)
Missing	48,617	32,099	16,518	23,392	8,707
Hospitalization within 30 days of index date	99,063 (26%)	66,386 (27%)	32,677 (24%)	49,380 (25%)	17,006 (31%)
Medication (any within last 1 year)					
Antidepressants	38,114 (9.8%)	32,214 (13%)	5,900 (4.3%)	27,737 (14%)	4,477 (8.1%)
Antipsychotics	12,059 (3.1%)	11,011 (4.4%)	1,048 (0.8%)	9,547 (4.9%)	1,464 (2.7%)
Antihypertensives	80,737 (21%)	68,912 (28%)	11,825 (8.5%)	57,025 (29%)	11,887 (22%)
Statins	37,744 (9.7%)	32,296 (13%)	5,448 (3.9%)	26,857 (14%)	5,439 (9.9%)

Immunosuppressants	26,771 (6.9%)	22,481 (9.0%)	4,290 (3.1%)	17,269 (8.9%)	5,212 (9.5%)
Anthropometry closest within last 1 year					
Height	66.2 (4.0)	66.2 (4.0)	NA (NA)	66.2 (4.0)	66.1 (4.0)
<i>Missing</i>	139,759	1,442	138,317	0	1,442
BMI	29.5 (7.4)	29.5 (7.4)	NA (NA)	29.5 (7.4)	29.4 (7.4)
<i>Missing</i>	138,317	0	138,317		
Systolic BP	125.9 (18.6)	125.8 (18.6)	126.6 (18.3)	125.9 (18.6)	125.3 (18.7)
<i>Missing</i>	143,751	30,502	113,249	16,973	13,529
Labs within last 1 year					
HbA1c (%)	6.2 (1.6)	6.3 (1.7)	6.0 (1.3)	6.3 (1.7)	6.2 (1.6)
<i>Missing</i>	323,579	201,296	122,283	155,661	45,635
Glucose (mg/dL)	112.8 (46.9)	113.6 (47.3)	110.2 (45.8)	113.8 (47.7)	113.2 (45.6)
<i>Missing</i>	204,147	108,989	95,158	84,112	24,877
ALT	17.0 (12.0, 26.0)	17.0 (12.0, 26.0)	18.0 (13.0, 26.0)	17.0 (12.0, 26.0)	18.0 (12.0, 27.0)
<i>Missing</i>	230,313	130,240	100,073	101,189	29,051
AST	20.0 (16.0, 26.0)	20.0 (16.0, 26.0)	20.0 (16.0, 25.0)	20.0 (16.0, 26.0)	20.0 (16.0, 26.0)
<i>Missing</i>	228,832	128,790	100,042	99,874	28,916
Serum Creatinine	0.8 (0.7, 1.0)	0.8 (0.7, 1.1)	0.8 (0.7, 1.0)	0.9 (0.7, 1.1)	0.8 (0.7, 1.0)
<i>Missing</i>	206,250	111,019	95,231	86,029	24,990
HDL	51.7 (16.7)	50.8 (16.9)	54.0 (16.1)	50.9 (17.0)	50.6 (16.4)
<i>Missing</i>	312,407	194,042	118,365	148,261	45,781
LDL	79.6 (52.0)	83.1 (49.9)	70.3 (56.1)	87.1 (48.2)	65.3 (53.7)
<i>Missing</i>	308,329	191,750	116,579	147,313	44,437
Diagnosis codes for comorbidities within last 2 years					
Obesity	12,014 (3.1%)	10,234 (4.1%)	1,780 (1.3%)	8,656 (4.4%)	1,578 (2.9%)
Cardiovascular	14,797 (3.8%)	12,533 (5.0%)	2,264 (1.6%)	10,325 (5.3%)	2,208 (4.0%)
Cerebrovascular	684 (0.2%)	549 (0.2%)	135 (<0.1%)	448 (0.2%)	101 (0.2%)
Hypertension	29,399 (7.6%)	23,882 (9.6%)	5,517 (4.0%)	19,531 (10%)	4,351 (7.9%)
Pulmonary disease	9,158 (2.4%)	7,518 (3.0%)	1,640 (1.2%)	6,317 (3.2%)	1,201 (2.2%)
Hyperlipidemia	21,787 (5.6%)	18,607 (7.5%)	3,180 (2.3%)	15,493 (8.0%)	3,114 (5.7%)

Supplementary Table 3. Socio-demographic, clinical and community characteristics of exposure cohorts after weighting

	Overall	Exposed	Historical	Unexposed
<i>Weighted N</i>	190,028	25,526	149,031	15,471
Female (%)	117,941 (62%)	16,464 (64%)	91,688 (62%)	9,789 (63%)
Age (years)	51.8 (19.0)	49.4 (18.6)	52.6 (19.0)	48.5 (18.4)
Race/ethnicity				
NH White	98,384 (51.8%)	11,726 (45.9%)	78,626 (52.8%)	8,031 (51.9%)
NH Black	41,248 (21.7%)	6,639 (26.0%)	30,970 (20.8%)	3,639 (23.5%)
Hispanic	39,543 (20.8%)	5,778 (22.6%)	30,832 (20.7%)	2,932 (19.0%)
Smoking				
Yes	91,930 (48%)	11,608 (45%)	71,788 (48%)	8,534 (55%)
Health System				
Source 1	72,287 (44%)	9,675 (39%)	55,894 (45%)	6,718 (43%)
Source 2	35,373 (22%)	4,677 (19%)	27,634 (22%)	3,063 (20%)
Source 3	18,667 (11%)	3,010 (12%)	14,350 (12%)	1,308 (8.5%)
Source 4	14,571 (8.9%)	3,187 (13%)	9,649 (7.8%)	1,734 (11%)
Source 5	8,945 (5.5%)	1,619 (6.5%)	5,797 (4.7%)	1,529 (9.9%)
Source 6	789 (0.5%)	117 (0.5%)	572 (0.5%)	100 (0.6%)
Source 7	13,448 (8.2%)	2,615 (11%)	9,813 (7.9%)	1,020 (6.6%)
Primary Insurance				
Medicare	28,774 (18%)	3,508 (14%)	22,389 (18%)	2,877 (19%)
Medicaid	13,715 (8.4%)	1,969 (7.9%)	10,379 (8.4%)	1,367 (8.8%)
Other Government	4,223 (2.6%)	727 (2.9%)	3,191 (2.6%)	305 (2.0%)
Private	64,524 (45%)	10,845 (53%)	47,759 (42%)	5,920 (51%)
No Insurance	3,053 (1.9%)	339 (1.4%)	2,068 (1.7%)	647 (4.2%)
No Information	39,675 (24%)	5,090 (20%)	32,399 (26%)	2,186 (14%)
Hospitalization within 30 days of index date	52,528 (28%)	7,125 (28%)	43,728 (29%)	1,675 (11%)
Medication (any within last 1 year)				
Antidepressants	28,094 (15%)	3,792 (15%)	22,159 (15%)	2,143 (14%)
Antipsychotics	10,248 (5.4%)	1,411 (5.5%)	8,118 (5.4%)	719 (4.6%)
Antihypertensives	60,532 (32%)	8,098 (32%)	48,141 (32%)	4,293 (28%)
Statins	29,913 (16%)	3,880 (15%)	24,132 (16%)	1,900 (12%)
Immunosuppressants	20,888 (11%)	3,149 (12%)	16,259 (11%)	1,480 (9.6%)
Anthropometry closest within 1 year				
Height	66.2 (4.0)	66.2 (4.0)	66.2 (4.1)	66.1 (4.0)
<i>Missing</i>	1,250	227	980	43
BMI	29.5 (7.4)	30.3 (7.7)	29.4 (7.4)	29.2 (7.3)
Systolic BP	125.7 (18.6)	125.4 (18.0)	125.7 (18.8)	125.6 (18.1)
<i>Missing</i>	21,232	3,499	16,550	1,183
Labs within last 1 year				
HbA1c (%)	6.3 (1.7)	6.3 (1.8)	6.2 (1.6)	6.2 (1.6)
<i>Missing</i>	152,493	19,935	119,298	13,260

Glucose (mg/dL)	113.9 (47.5)	114.7 (49.2)	114.0 (47.5)	110.9 (44.1)
<i>Missing</i>	80,265	10,435	61,998	7,832
ALT	17.0 (12.0, 26.0)	17.0 (12.0, 26.0)	17.0 (12.0, 26.0)	17.0 (12.0, 26.0)
<i>Missing</i>	96,773	12,490	74,991	9,292
AST	20.0 (16.0, 26.0)	19.0 (15.0, 25.0)	20.0 (16.0, 26.0)	19.0 (16.0, 25.0)
<i>Missing</i>	95,684	12,306	74,227	9,151
Serum Creatinine	0.9 (0.7, 1.1)	0.8 (0.7, 1.0)	0.9 (0.7, 1.1)	0.8 (0.7, 1.0)
<i>Missing</i>	81,720	10,589	63,149	7,981
HDL	50.8 (16.8)	50.3 (15.8)	50.8 (16.8)	51.8 (18.9)
<i>Missing</i>	146,292	19,095	114,736	12,461
LDL	83.1 (49.7)	83.4 (52.1)	82.0 (49.7)	94.6 (43.0)
<i>Missing</i>	144,722	18,760	113,586	12,376
Diagnosis codes for comorbidities within last 2 years				
Obesity	7,409 (3.9%)	1,180 (4.6%)	5,705 (3.8%)	524 (3.4%)
Cardiovascular	9,113 (4.8%)	1,222 (4.8%)	7,171 (4.8%)	719 (4.6%)
Cerebrovascular	376 (0.2%)	53 (0.2%)	285 (0.2%)	38 (0.2%)
Hypertension	17,168 (9.0%)	2,369 (9.3%)	13,323 (8.9%)	1,477 (9.5%)
Pulmonary disease	5,608 (3.0%)	805 (3.2%)	4,433 (3.0%)	371 (2.4%)
Hyperlipidemia	13,253 (7.0%)	1,990 (7.8%)	10,181 (6.8%)	1,083 (7.0%)

Values are summarized as weighted mean (weighted SD) or weighted median (weighted 25th percentile, weighted 75th percentile) or weighted frequency (weighted %).

Supplementary Table 4. Changes during follow-up period in body mass index

	Exposed	Unexposed	Historical
Body mass index	Mar 2020 – Feb 2022	Mar 2020 – Feb 2022	Mar 2018 – Feb 2020
Number of participants with any observation in follow-up	32,384	127,142	35,266
Time to first follow-up visit (days relative to origin date [T0 + 30])	39 [12, 107]	33 [11, 98]	74 [22, 180]
BMI at first follow-up encounter after T0+30 days (kg/m ²)	29.3 [24.9, 34.9]	27.9 [23.9, 33]	27.8 [23.8, 32.8]
Number of BMI measurements after T0+30	3 [1, 6]	3 [1, 7]	4 [2, 8]
Length of follow-up (days relative to origin date [T0 + 30])	178 [76, 357]	212 [85, 374]	464 [271, 592]
Maximum change in BMI during follow-up (kg/m ²)	0.9 [0, 2.6]	1.1 [0, 2.7]	1.3 [0.2, 3]

All values are unweighted median (25th percentile, 75th percentile)

Supplementary Table 5. Modeled marginal estimates of changes in body mass index during follow-up by exposure cohort

		Exposed	Unexposed	Historical
Female	Time _{0,Cohort}	29.8 (29.4, 30.2)	29.6 (29.4, 29.8)	29.4 (29, 29.8)
	Time _{0,Cohort} - Time _{0,Exposed}	Ref	-0.16 (-0.23, -0.1)	-0.36 (-0.45, -0.27)
	Δ _{0→100days}	-0.02 (-0.05, 0.01)	-0.03 (-0.05, -0.02)	0.05 (0.03, 0.07)
	Δ _{0→100days, Cohort} - Δ _{0→100days, Exposed}	Ref	-0.01 (-0.05, 0.03)	0.07 (0.03, 0.11)
Male	Time _{0,Cohort}	29.5 (29, 30.1)	29.6 (29.4, 29.9)	29.5 (28.9, 30)
	Time _{0,Cohort} - Time _{0,Exposed}	Ref	0.07 (-0.02, 0.16)	-0.08 (-0.2, 0.03)
	Δ _{0→100days}	0.03 (-0.02, 0.07)	-0.05 (-0.06, -0.03)	0 (-0.02, 0.03)
	Δ _{0→100days, Cohort} - Δ _{0→100days, Exposed}	Ref	-0.07 (-0.12, -0.02)	-0.03 (-0.08, 0.03)
18 to 39 years	Time _{0,Cohort}	29.6 (28.9, 30.2)	29.2 (28.8, 29.7)	29.3 (28.6, 29.9)
	Time _{0,Cohort} - Time _{0,Exposed}	Ref	-0.32 (-0.42, -0.22)	-0.30 (-0.42, -0.17)
	Δ _{0→100days}	0.06 (0.01, 0.11)	0.07 (0.05, 0.1)	0.09 (0.06, 0.12)
	Δ _{0→100days, Cohort} - Δ _{0→100days, Exposed}	Ref	0.01 (-0.04, 0.07)	0.04 (-0.02, 0.09)
40 to 64 years	Time _{0,Cohort}	29.8 (29.1, 30.4)	29.7 (29.4, 30.1)	29.5 (28.8, 30.1)
	Time _{0,Cohort} - Time _{0,Exposed}	Ref	-0.04 (-0.12, 0.04)	-0.30 (-0.41, -0.20)
	Δ _{0→100days}	-0.01 (-0.05, 0.04)	-0.04 (-0.06, -0.03)	0.02 (0, 0.04)
	Δ _{0→100days, Cohort} - Δ _{0→100days, Exposed}	Ref	-0.04 (-0.08, 0.01)	0.03 (-0.02, 0.08)
65 and older	Time _{0,Cohort}	29.6 (29.1, 30.1)	29.7 (29.4, 29.9)	29.5 (29, 30)
	Time _{0,Cohort} - Time _{0,Exposed}	Ref	0.09 (-0.01, 0.18)	-0.09 (-0.22, 0.03)
	Δ _{0→100days}	-0.05 (-0.1, 0.01)	-0.09 (-0.11, -0.08)	-0.01 (-0.04, 0.01)
	Δ _{0→100days, Cohort} - Δ _{0→100days, Exposed}	Ref	-0.05 (-0.1, 0.01)	0.03 (-0.02, 0.09)
Hispanic	Time _{0,Cohort}	29.4 (29.1, 29.7)	29.3 (28.6, 30)	29.4 (29, 29.7)
	Time _{0,Cohort} - Time _{0,Exposed}	Ref	-0.06 (-0.17, 0.05)	-0.01 (-0.16, 0.13)
	Δ _{0→100days}	0.03 (-0.02, 0.08)	-0.02 (-0.05, 0.01)	-0.02 (-0.05, 0.02)
	Δ _{0→100days, Cohort} - Δ _{0→100days, Exposed}	Ref	-0.05 (-0.11, 0.01)	-0.05 (-0.11, 0.01)
Non-Hispanic White	Time _{0,Cohort}	29.4 (28.7, 30)	29.3 (28.9, 29.6)	29 (28.3, 29.8)
	Time _{0,Cohort} - Time _{0,Exposed}	Ref	-0.08 (-0.16, -0.01)	-0.32 (-0.42, -0.23)
	Δ _{0→100days}	-0.03 (-0.07, 0.01)	-0.04 (-0.06, -0.03)	0.04 (0.02, 0.06)

	$\Delta_{0 \rightarrow 100 \text{days, Cohort}} - \Delta_{0 \rightarrow 100 \text{days, Exposed}}$	Ref	-0.01 (-0.05, 0.03)	0.07 (0.03, 0.11)
Non-Hispanic Black	$\text{Time}_{0, \text{Cohort}}$	29.5 (28.9, 30.2)	29.4 (28.7, 30)	29.2 (28.5, 29.9)
	$\text{Time}_{0, \text{Cohort}} - \text{Time}_{0, \text{Exposed}}$	Ref	-0.13 (-0.25, -0.02)	-0.34 (-0.48, -0.19)
	$\Delta_{0 \rightarrow 100 \text{days}}$	0.01 (-0.05, 0.07)	-0.03 (-0.06, -0.01)	0.05 (0.01, 0.08)
	$\Delta_{0 \rightarrow 100 \text{days, Cohort}} - \Delta_{0 \rightarrow 100 \text{days, Exposed}}$	Ref	-0.04 (-0.11, 0.02)	0.04 (-0.03, 0.1)
Not Hospitalized	$\text{Time}_{0, \text{Cohort}}$	29.7 (29.4, 30.1)	29.7 (29.5, 29.9)	29.5 (29.2, 29.8)
	$\text{Time}_{0, \text{Cohort}} - \text{Time}_{0, \text{Exposed}}$	Ref	-0.04 (-0.09, 0.01)	-0.26 (-0.33, -0.2)
	$\Delta_{0 \rightarrow 100 \text{days}}$	0 (-0.03, 0.02)	-0.04 (-0.05, -0.03)	0.03 (0.01, 0.04)
	$\Delta_{0 \rightarrow 100 \text{days, Cohort}} - \Delta_{0 \rightarrow 100 \text{days, Exposed}}$	Ref	-0.04 (-0.07, -0.01)	0.03 (0, 0.06)
Hospitalized	$\text{Time}_{0, \text{Cohort}}$	29.2 (28.4, 29.9)	29 (28.7, 29.3)	29.1 (27.8, 30.3)
	$\text{Time}_{0, \text{Cohort}} - \text{Time}_{0, \text{Exposed}}$	Ref	-0.14 (-0.26, -0.03)	-0.09 (-0.31, 0.13)
	$\Delta_{0 \rightarrow 100 \text{days}}$	0.01 (-0.05, 0.08)	-0.02 (-0.04, 0.01)	0.05 (-0.02, 0.11)
	$\Delta_{0 \rightarrow 100 \text{days, Cohort}} - \Delta_{0 \rightarrow 100 \text{days, Exposed}}$	Ref	-0.03 (-0.1, 0.04)	0.04 (-0.06, 0.13)

Supplementary Table 6. Modeled marginal estimates of changes in body mass index during follow-up by exposure cohort among those with 100 days of follow-up and at least two BMI encounters, n = 1,103,882 observations from 124,934 patients

		Exposed	Unexposed	Historical
Overall	Time _{0,Cohort}	29.4 (29, 29.9)	29.4 (29.2, 29.6)	29.1 (28.7, 29.5)
	Time _{0,Cohort} - Time _{0,Exposed}	Ref	-0.06 (-0.13, 0.01)	-0.29 (-0.37, -0.21)
	Δ _{0→100days}	0 (-0.03, 0.03)	-0.04 (-0.05, -0.03)	0.03 (0.01, 0.04)
	Δ _{0→100days, Cohort} - Δ _{0→100days, Exposed}	Ref	-0.03 (-0.07, 0)	0.03 (0, 0.06)
Female	Time _{0,Cohort}	29.9 (29.3, 30.4)	29.7 (29.4, 30)	29.5 (29, 29.9)
	Time _{0,Cohort} - Time _{0,Exposed}	Ref	-0.16 (-0.25, -0.08)	-0.41 (-0.51, -0.31)
	Δ _{0→100days}	-0.02 (-0.06, 0.01)	-0.03 (-0.05, -0.02)	0.05 (0.03, 0.07)
	Δ _{0→100days, Cohort} - Δ _{0→100days, Exposed}	Ref	-0.01 (-0.05, 0.03)	0.07 (0.03, 0.11)
Male	Time _{0,Cohort}	29.6 (28.9, 30.3)	29.7 (29.4, 30)	29.6 (29, 30.1)
	Time _{0,Cohort} - Time _{0,Exposed}	Ref	0.07 (-0.04, 0.18)	-0.08 (-0.21, 0.05)
	Δ _{0→100days}	0.03 (-0.02, 0.07)	-0.05 (-0.07, -0.03)	0 (-0.02, 0.03)
	Δ _{0→100days, Cohort} - Δ _{0→100days, Exposed}	Ref	-0.07 (-0.12, -0.02)	-0.03 (-0.08, 0.03)
18 to 39 years	Time _{0,Cohort}	29.6 (28.8, 30.5)	29.3 (28.8, 29.9)	29.3 (28.5, 30.1)
	Time _{0,Cohort} - Time _{0,Exposed}	Ref	-0.33 (-0.46, -0.21)	-0.33 (-0.48, -0.18)
	Δ _{0→100days}	0.06 (0.01, 0.11)	0.07 (0.05, 0.1)	0.09 (0.06, 0.12)
	Δ _{0→100days, Cohort} - Δ _{0→100days, Exposed}	Ref	0.01 (-0.04, 0.07)	0.04 (-0.02, 0.09)
40 to 64 years	Time _{0,Cohort}	29.8 (29, 30.7)	29.8 (29.4, 30.2)	29.5 (28.8, 30.2)
	Time _{0,Cohort} - Time _{0,Exposed}	Ref	-0.03 (-0.13, 0.07)	-0.31 (-0.43, -0.19)
	Δ _{0→100days}	-0.01 (-0.05, 0.04)	-0.05 (-0.06, -0.03)	0.02 (0, 0.04)
	Δ _{0→100days, Cohort} - Δ _{0→100days, Exposed}	Ref	-0.04 (-0.08, 0.01)	0.03 (-0.02, 0.08)
65 and older	Time _{0,Cohort}	29.8 (29.1, 30.4)	29.8 (29.5, 30.1)	29.6 (29.1, 30.1)
	Time _{0,Cohort} - Time _{0,Exposed}	Ref	0.07 (-0.06, 0.19)	-0.15 (-0.3, 0.00)
	Δ _{0→100days}	-0.05 (-0.1, 0)	-0.09 (-0.11, -0.08)	-0.01 (-0.04, 0.01)
	Δ _{0→100days, Cohort} - Δ _{0→100days, Exposed}	Ref	-0.05 (-0.1, 0.01)	0.03 (-0.02, 0.09)
Hispanic	Time _{0,Cohort}	29.5 (29.1, 29.9)	29.4 (28.6, 30.3)	29.4 (29, 29.9)
	Time _{0,Cohort} - Time _{0,Exposed}	Ref	-0.01 (-0.15, 0.13)	-0.02 (-0.19, 0.15)

	$\Delta_{0 \rightarrow 100 \text{days}}$	0.03 (-0.03, 0.08)	-0.02 (-0.05, 0.01)	-0.02 (-0.05, 0.02)
	$\Delta_{0 \rightarrow 100 \text{days, Cohort}} - \Delta_{0 \rightarrow 100 \text{days, Exposed}}$	Ref	-0.05 (-0.11, 0.01)	-0.04 (-0.11, 0.02)
Non-Hispanic White	$\text{Time}_{0, \text{Cohort}}$	29.5 (28.7, 30.2)	29.4 (29, 29.8)	29.1 (28.3, 30)
	$\text{Time}_{0, \text{Cohort}} - \text{Time}_{0, \text{Exposed}}$	Ref	-0.09 (-0.19, 0)	-0.33 (-0.44, -0.22)
	$\Delta_{0 \rightarrow 100 \text{days}}$	-0.03 (-0.07, 0.01)	-0.05 (-0.06, -0.03)	0.04 (0.02, 0.06)
	$\Delta_{0 \rightarrow 100 \text{days, Cohort}} - \Delta_{0 \rightarrow 100 \text{days, Exposed}}$	Ref	-0.01 (-0.06, 0.03)	0.07 (0.03, 0.12)
Non-Hispanic Black	$\text{Time}_{0, \text{Cohort}}$	29.6 (28.9, 30.3)	29.5 (28.6, 30.3)	29.2 (28.5, 30)
	$\text{Time}_{0, \text{Cohort}} - \text{Time}_{0, \text{Exposed}}$	Ref	-0.13 (-0.27, 0)	-0.39 (-0.55, -0.22)
	$\Delta_{0 \rightarrow 100 \text{days}}$	0.01 (-0.05, 0.07)	-0.03 (-0.06, -0.01)	0.05 (0.01, 0.08)
	$\Delta_{0 \rightarrow 100 \text{days, Cohort}} - \Delta_{0 \rightarrow 100 \text{days, Exposed}}$	Ref	-0.04 (-0.1, 0.02)	0.04 (-0.03, 0.1)
Not Hospitalized	$\text{Time}_{0, \text{Cohort}}$	29.8 (29.4, 30.2)	29.8 (29.5, 30)	29.5 (29.2, 29.9)
	$\text{Time}_{0, \text{Cohort}} - \text{Time}_{0, \text{Exposed}}$	Ref	-0.06 (-0.13, 0)	-0.3 (-0.37, -0.22)
	$\Delta_{0 \rightarrow 100 \text{days}}$	-0.01 (-0.03, 0.02)	-0.04 (-0.06, -0.03)	0.03 (0.01, 0.04)
	$\Delta_{0 \rightarrow 100 \text{days, Cohort}} - \Delta_{0 \rightarrow 100 \text{days, Exposed}}$	Ref	-0.04 (-0.07, -0.01)	0.03 (0, 0.06)
Hospitalized	$\text{Time}_{0, \text{Cohort}}$	29.3 (28.3, 30.2)	29.2 (28.8, 29.6)	29.1 (27.7, 30.5)
	$\text{Time}_{0, \text{Cohort}} - \text{Time}_{0, \text{Exposed}}$	Ref	-0.08 (-0.23, 0.07)	-0.15 (-0.41, 0.10)
	$\Delta_{0 \rightarrow 100 \text{days}}$	0.01 (-0.06, 0.07)	-0.02 (-0.04, 0)	0.05 (-0.02, 0.12)
	$\Delta_{0 \rightarrow 100 \text{days, Cohort}} - \Delta_{0 \rightarrow 100 \text{days, Exposed}}$	Ref	-0.03 (-0.1, 0.04)	0.04 (-0.05, 0.14)

Supplementary Table 7. Modeled marginal estimates of changes in body mass index during follow-up by exposure cohort after adjusting for number and type of encounters between BMI measurements, n = 1,230,631 observations from 194,792 patients

		Exposed	Unexposed	Historical
Overall	Time _{0,Cohort}	29.3 (29, 29.7)	29.3 (29.1, 29.4)	29.1 (28.7, 29.4)
	Time _{0,Cohort} - Time _{0,Exposed}	Ref	-0.07 (-0.12, -0.01)	-0.27 (-0.34, -0.2)
	Δ _{0→100days}	0 (-0.03, 0.03)	-0.04 (-0.05, -0.02)	0.03 (0.02, 0.04)
	Δ _{0→100days, Cohort} - Δ _{0→100days, Exposed}	Ref	-0.04 (-0.06, -0.01)	0.03 (0, 0.06)
Female	Time _{0,Cohort}	29.8 (29.3, 30.2)	29.6 (29.4, 29.8)	29.4 (29, 29.8)
	Time _{0,Cohort} - Time _{0,Exposed}	Ref	-0.16 (-0.23, -0.09)	-0.36 (-0.45, -0.27)
	Δ _{0→100days}	-0.02 (-0.05, 0.01)	-0.03 (-0.04, -0.01)	0.05 (0.03, 0.07)
	Δ _{0→100days, Cohort} - Δ _{0→100days, Exposed}	Ref	-0.01 (-0.05, 0.03)	0.07 (0.03, 0.11)
Male	Time _{0,Cohort}	29.5 (29, 30.1)	29.6 (29.4, 29.9)	29.5 (28.9, 30)
	Time _{0,Cohort} - Time _{0,Exposed}	Ref	0.07 (-0.02, 0.16)	-0.09 (-0.2, 0.03)
	Δ _{0→100days}	0.03 (-0.02, 0.07)	-0.05 (-0.06, -0.03)	0 (-0.02, 0.03)
	Δ _{0→100days, Cohort} - Δ _{0→100days, Exposed}	Ref	-0.07 (-0.12, -0.02)	-0.03 (-0.08, 0.03)
18 to 39 years	Time _{0,Cohort}	29.6 (28.9, 30.2)	29.2 (28.8, 29.7)	29.3 (28.6, 29.9)
	Time _{0,Cohort} - Time _{0,Exposed}	Ref	-0.32 (-0.42, -0.22)	-0.3 (-0.43, -0.17)
	Δ _{0→100days}	0.06 (0.01, 0.11)	0.07 (0.05, 0.1)	0.09 (0.06, 0.12)
	Δ _{0→100days, Cohort} - Δ _{0→100days, Exposed}	Ref	0.02 (-0.04, 0.07)	0.03 (-0.02, 0.09)
40 to 64 years	Time _{0,Cohort}	29.8 (29.1, 30.4)	29.7 (29.4, 30.1)	29.5 (28.8, 30.1)
	Time _{0,Cohort} - Time _{0,Exposed}	Ref	-0.04 (-0.12, 0.04)	-0.3 (-0.41, -0.2)
	Δ _{0→100days}	-0.01 (-0.05, 0.04)	-0.04 (-0.06, -0.03)	0.02 (0, 0.04)
	Δ _{0→100days, Cohort} - Δ _{0→100days, Exposed}	Ref	-0.04 (-0.08, 0.01)	0.03 (-0.02, 0.07)
65 and older	Time _{0,Cohort}	29.6 (29.1, 30.1)	29.7 (29.4, 29.9)	29.5 (29, 30)
	Time _{0,Cohort} - Time _{0,Exposed}	Ref	0.09 (-0.01, 0.19)	-0.1 (-0.22, 0.03)
	Δ _{0→100days}	-0.04 (-0.09, 0.01)	-0.09 (-0.11, -0.08)	-0.01 (-0.04, 0.01)
	Δ _{0→100days, Cohort} - Δ _{0→100days, Exposed}	Ref	-0.05 (-0.1, 0.01)	0.03 (-0.02, 0.09)
Hispanic	Time _{0,Cohort}	29.4 (29.1, 29.7)	29.3 (28.6, 30)	29.4 (29, 29.7)
	Time _{0,Cohort} - Time _{0,Exposed}	Ref	-0.06 (-0.17, 0.05)	-0.01 (-0.16, 0.13)

	$\Delta_{0 \rightarrow 100 \text{days}}$	0.03 (-0.02, 0.08)	-0.02 (-0.05, 0.01)	-0.02 (-0.05, 0.02)
	$\Delta_{0 \rightarrow 100 \text{days, Cohort}} - \Delta_{0 \rightarrow 100 \text{days, Exposed}}$	Ref	-0.05 (-0.11, 0.01)	-0.05 (-0.11, 0.01)
Non-Hispanic White	$\text{Time}_{0, \text{Cohort}}$	29.4 (28.7, 30)	29.3 (28.9, 29.6)	29 (28.3, 29.8)
	$\text{Time}_{0, \text{Cohort}} - \text{Time}_{0, \text{Exposed}}$	Ref	-0.08 (-0.15, 0)	-0.32 (-0.42, -0.23)
	$\Delta_{0 \rightarrow 100 \text{days}}$	-0.03 (-0.07, 0.01)	-0.04 (-0.06, -0.03)	0.04 (0.02, 0.06)
	$\Delta_{0 \rightarrow 100 \text{days, Cohort}} - \Delta_{0 \rightarrow 100 \text{days, Exposed}}$	Ref	-0.01 (-0.05, 0.03)	0.07 (0.03, 0.11)
Non-Hispanic Black	$\text{Time}_{0, \text{Cohort}}$	29.5 (28.9, 30.2)	29.4 (28.7, 30)	29.2 (28.5, 29.9)
	$\text{Time}_{0, \text{Cohort}} - \text{Time}_{0, \text{Exposed}}$	Ref	-0.13 (-0.24, -0.02)	-0.34 (-0.48, -0.19)
	$\Delta_{0 \rightarrow 100 \text{days}}$	0.01 (-0.05, 0.07)	-0.03 (-0.06, -0.01)	0.05 (0.02, 0.08)
	$\Delta_{0 \rightarrow 100 \text{days, Cohort}} - \Delta_{0 \rightarrow 100 \text{days, Exposed}}$	Ref	-0.04 (-0.11, 0.02)	0.04 (-0.03, 0.1)
Not Hospitalized	$\text{Time}_{0, \text{Cohort}}$	29.7 (29.4, 30.1)	29.7 (29.5, 29.9)	29.5 (29.2, 29.8)
	$\text{Time}_{0, \text{Cohort}} - \text{Time}_{0, \text{Exposed}}$	Ref	-0.04 (-0.09, 0.01)	-0.27 (-0.33, -0.2)
	$\Delta_{0 \rightarrow 100 \text{days}}$	0 (-0.03, 0.02)	-0.04 (-0.05, -0.03)	0.03 (0.01, 0.04)
	$\Delta_{0 \rightarrow 100 \text{days, Cohort}} - \Delta_{0 \rightarrow 100 \text{days, Exposed}}$	Ref	-0.04 (-0.07, -0.01)	0.03 (0, 0.06)
Hospitalized	$\text{Time}_{0, \text{Cohort}}$	29.2 (28.4, 29.9)	29 (28.7, 29.3)	29.1 (27.8, 30.4)
	$\text{Time}_{0, \text{Cohort}} - \text{Time}_{0, \text{Exposed}}$	Ref	-0.14 (-0.25, -0.02)	-0.09 (-0.31, 0.13)
	$\Delta_{0 \rightarrow 100 \text{days}}$	0.01 (-0.05, 0.08)	-0.02 (-0.04, 0.01)	0.05 (-0.02, 0.12)
	$\Delta_{0 \rightarrow 100 \text{days, Cohort}} - \Delta_{0 \rightarrow 100 \text{days, Exposed}}$	Ref	-0.03 (-0.1, 0.04)	0.04 (-0.06, 0.13)

Supplementary Table 8. Modeled marginal estimates of changes in body mass index during follow-up by exposure cohort after adjusting for COVID-19 cases and test positivity rate, n = 1,230,631 observations from 194,792 patients

		Exposed	Unexposed	Historical
Overall	Time _{0,Cohort}	29.3 (29, 29.7)	29.3 (29.1, 29.4)	29.1 (28.7, 29.4)
	Time _{0,Cohort} - Time _{0,Exposed}	Ref	-0.07 (-0.12, -0.01)	-0.27 (-0.34, -0.2)
	Δ _{0→100days}	0 (-0.03, 0.03)	-0.03 (-0.05, -0.02)	0.03 (0.01, 0.04)
	Δ _{0→100days, Cohort} - Δ _{0→100days, Exposed}	Ref	-0.04 (-0.07, -0.01)	0.03 (0, 0.06)
Female	Time _{0,Cohort}	29.8 (29.3, 30.2)	29.6 (29.4, 29.8)	29.4 (29, 29.8)
	Time _{0,Cohort} - Time _{0,Exposed}	Ref	-0.16 (-0.23, -0.1)	-0.36 (-0.45, -0.28)
	Δ _{0→100days}	-0.02 (-0.05, 0.02)	-0.03 (-0.04, -0.01)	0.05 (0.03, 0.07)
	Δ _{0→100days, Cohort} - Δ _{0→100days, Exposed}	Ref	-0.01 (-0.05, 0.03)	0.07 (0.03, 0.11)
Male	Time _{0,Cohort}	29.5 (29, 30.1)	29.6 (29.4, 29.9)	29.5 (28.9, 30)
	Time _{0,Cohort} - Time _{0,Exposed}	Ref	0.07 (-0.02, 0.16)	-0.09 (-0.2, 0.02)
	Δ _{0→100days}	0.03 (-0.02, 0.08)	-0.04 (-0.06, -0.03)	0 (-0.02, 0.03)
	Δ _{0→100days, Cohort} - Δ _{0→100days, Exposed}	Ref	-0.07 (-0.12, -0.02)	-0.03 (-0.08, 0.03)
18 to 39 years	Time _{0,Cohort}	29.6 (28.9, 30.2)	29.2 (28.8, 29.7)	29.3 (28.6, 29.9)
	Time _{0,Cohort} - Time _{0,Exposed}	Ref	-0.32 (-0.42, -0.23)	-0.3 (-0.43, -0.18)
	Δ _{0→100days}	0.06 (0.01, 0.11)	0.07 (0.05, 0.1)	0.09 (0.06, 0.12)
	Δ _{0→100days, Cohort} - Δ _{0→100days, Exposed}	Ref	0.01 (-0.04, 0.07)	0.03 (-0.02, 0.09)
40 to 64 years	Time _{0,Cohort}	29.8 (29.1, 30.4)	29.7 (29.4, 30.1)	29.5 (28.8, 30.1)
	Time _{0,Cohort} - Time _{0,Exposed}	Ref	-0.04 (-0.12, 0.04)	-0.31 (-0.41, -0.2)
	Δ _{0→100days}	-0.01 (-0.05, 0.04)	-0.04 (-0.06, -0.02)	0.02 (0, 0.04)
	Δ _{0→100days, Cohort} - Δ _{0→100days, Exposed}	Ref	-0.04 (-0.08, 0.01)	0.03 (-0.02, 0.07)
65 and older	Time _{0,Cohort}	29.6 (29.1, 30.1)	29.7 (29.4, 29.9)	29.5 (29, 30)
	Time _{0,Cohort} - Time _{0,Exposed}	Ref	0.09 (-0.01, 0.18)	-0.1 (-0.22, 0.03)
	Δ _{0→100days}	-0.04 (-0.09, 0.01)	-0.09 (-0.11, -0.07)	-0.01 (-0.04, 0.01)
	Δ _{0→100days, Cohort} - Δ _{0→100days, Exposed}	Ref	-0.05 (-0.1, 0.01)	0.03 (-0.03, 0.09)
Hispanic	Time _{0,Cohort}	29.4 (29.1, 29.7)	29.3 (28.6, 30)	29.4 (29, 29.7)
	Time _{0,Cohort} - Time _{0,Exposed}	Ref	-0.06 (-0.17, 0.05)	-0.02 (-0.17, 0.13)

	$\Delta_0 \rightarrow 100\text{days}$	0.03 (-0.02, 0.08)	-0.02 (-0.05, 0.01)	-0.02 (-0.05, 0.02)
	$\Delta_0 \rightarrow 100\text{days, Cohort} - \Delta_0 \rightarrow 100\text{days, Exposed}$	Ref	-0.05 (-0.11, 0.01)	-0.05 (-0.11, 0.01)
Non-Hispanic White	$\text{Time}_0, \text{Cohort}$	29.4 (28.7, 30)	29.3 (28.9, 29.6)	29 (28.3, 29.8)
	$\text{Time}_0, \text{Cohort} - \text{Time}_0, \text{Exposed}$	Ref	-0.08 (-0.16, -0.01)	-0.33 (-0.42, -0.23)
	$\Delta_0 \rightarrow 100\text{days}$	-0.03 (-0.07, 0.01)	-0.04 (-0.06, -0.03)	0.04 (0.02, 0.06)
	$\Delta_0 \rightarrow 100\text{days, Cohort} - \Delta_0 \rightarrow 100\text{days, Exposed}$	Ref	-0.01 (-0.05, 0.03)	0.07 (0.02, 0.11)
Non-Hispanic Black	$\text{Time}_0, \text{Cohort}$	29.5 (28.9, 30.2)	29.4 (28.7, 30)	29.2 (28.4, 29.9)
	$\text{Time}_0, \text{Cohort} - \text{Time}_0, \text{Exposed}$	Ref	-0.13 (-0.25, -0.02)	-0.34 (-0.49, -0.19)
	$\Delta_0 \rightarrow 100\text{days}$	0.01 (-0.05, 0.07)	-0.03 (-0.06, -0.01)	0.05 (0.01, 0.08)
	$\Delta_0 \rightarrow 100\text{days, Cohort} - \Delta_0 \rightarrow 100\text{days, Exposed}$	Ref	-0.04 (-0.11, 0.02)	0.03 (-0.03, 0.1)
Not Hospitalized	$\text{Time}_0, \text{Cohort}$	29.7 (29.4, 30.1)	29.7 (29.5, 29.9)	29.5 (29.1, 29.8)
	$\text{Time}_0, \text{Cohort} - \text{Time}_0, \text{Exposed}$	Ref	-0.04 (-0.1, 0.01)	-0.27 (-0.34, -0.21)
	$\Delta_0 \rightarrow 100\text{days}$	0 (-0.02, 0.02)	-0.04 (-0.05, -0.03)	0.03 (0.01, 0.04)
	$\Delta_0 \rightarrow 100\text{days, Cohort} - \Delta_0 \rightarrow 100\text{days, Exposed}$	Ref	-0.04 (-0.07, -0.01)	0.03 (0, 0.06)
Hospitalized	$\text{Time}_0, \text{Cohort}$	29.2 (28.4, 29.9)	29 (28.7, 29.3)	29.1 (27.8, 30.3)
	$\text{Time}_0, \text{Cohort} - \text{Time}_0, \text{Exposed}$	Ref	-0.14 (-0.26, -0.03)	-0.1 (-0.32, 0.12)
	$\Delta_0 \rightarrow 100\text{days}$	0.02 (-0.05, 0.08)	-0.01 (-0.04, 0.01)	0.05 (-0.02, 0.11)
	$\Delta_0 \rightarrow 100\text{days, Cohort} - \Delta_0 \rightarrow 100\text{days, Exposed}$	Ref	-0.03 (-0.1, 0.04)	0.03 (-0.06, 0.13)


Supplementary Table 9. Modeled marginal estimates of changes in body mass index during follow-up by exposure cohort after adjusting for laboratory parameters with multiple imputation, n = 1,230,631 observations from 194,792 patients

		Exposed	Unexposed	Historical
Overall	Time _{0,Cohort}	29.4	29.3	29.1
	Time _{0,Cohort} - Time _{0,Exposed}	0	-0.06 (-0.11, 0)	-0.26 (-0.33, -0.2)
	Δ _{0→100days}	0 (-0.03, 0.03)	-0.04 (-0.05, -0.02)	0.03 (0.01, 0.04)
	Δ _{0→100days, Cohort} - Δ _{0→100days, Exposed}	0	-0.04 (-0.06, -0.01)	0.03 (0, 0.06)
Female	Time _{0,Cohort}	29.8	29.6	29.4
	Time _{0,Cohort} - Time _{0,Exposed}	0	-0.15 (-0.22, -0.09)	-0.36 (-0.45, -0.27)
	Δ _{0→100days}	-0.02 (-0.05, 0.01)	-0.03 (-0.05, -0.02)	0.05 (0.03, 0.07)
	Δ _{0→100days, Cohort} - Δ _{0→100days, Exposed}	0	-0.01 (-0.05, 0.03)	0.07 (0.03, 0.11)
Male	Time _{0,Cohort}	29.6	29.6	29.5
	Time _{0,Cohort} - Time _{0,Exposed}	0	0.08 (-0.01, 0.17)	-0.09 (-0.2, 0.02)
	Δ _{0→100days}	0.03 (-0.02, 0.07)	-0.05 (-0.06, -0.03)	0 (-0.02, 0.03)
	Δ _{0→100days, Cohort} - Δ _{0→100days, Exposed}	0	-0.07 (-0.12, -0.02)	-0.03 (-0.08, 0.03)
18 to 39 years	Time _{0,Cohort}	29.6	29.3	29.3
	Time _{0,Cohort} - Time _{0,Exposed}	0	-0.31 (-0.41, -0.21)	-0.3 (-0.42, -0.17)
	Δ _{0→100days}	0.06 (0.01, 0.11)	0.07 (0.05, 0.1)	0.09 (0.06, 0.12)
	Δ _{0→100days, Cohort} - Δ _{0→100days, Exposed}	0	0.01 (-0.04, 0.07)	0.04 (-0.02, 0.09)
40 to 64 years	Time _{0,Cohort}	29.8	29.8	29.5
	Time _{0,Cohort} - Time _{0,Exposed}	0	-0.03 (-0.11, 0.05)	-0.3 (-0.41, -0.19)
	Δ _{0→100days}	-0.01 (-0.05, 0.04)	-0.04 (-0.06, -0.03)	0.02 (0, 0.04)
	Δ _{0→100days, Cohort} - Δ _{0→100days, Exposed}	0	-0.04 (-0.08, 0.01)	0.03 (-0.02, 0.08)
65 and older	Time _{0,Cohort}	29.6	29.7	29.5
	Time _{0,Cohort} - Time _{0,Exposed}	0	0.1 (0, 0.2)	-0.09 (-0.21, 0.04)
	Δ _{0→100days}	-0.04 (-0.1, 0.01)	-0.09 (-0.11, -0.08)	-0.01 (-0.04, 0.01)
	Δ _{0→100days, Cohort} - Δ _{0→100days, Exposed}	0	-0.05 (-0.1, 0.01)	0.03 (-0.02, 0.09)
Hispanic	Time _{0,Cohort}	29.4	29.3	29.4
	Time _{0,Cohort} - Time _{0,Exposed}	0	-0.06 (-0.17, 0.05)	-0.02 (-0.16, 0.13)


	$\Delta_{0 \rightarrow 100 \text{days}}$	0.03 (-0.02, 0.08)	-0.02 (-0.05, 0.01)	-0.02 (-0.05, 0.02)
	$\Delta_{0 \rightarrow 100 \text{days, Cohort}} - \Delta_{0 \rightarrow 100 \text{days, Exposed}}$	0	-0.05 (-0.11, 0.01)	-0.05 (-0.11, 0.01)
Non-Hispanic White	$\text{Time}_{0, \text{Cohort}}$	29.4	29.3	29.1
	$\text{Time}_{0, \text{Cohort}} - \text{Time}_{0, \text{Exposed}}$	0	-0.07 (-0.15, 0)	-0.32 (-0.42, -0.23)
	$\Delta_{0 \rightarrow 100 \text{days}}$	-0.03 (-0.07, 0.01)	-0.04 (-0.06, -0.03)	0.04 (0.02, 0.06)
	$\Delta_{0 \rightarrow 100 \text{days, Cohort}} - \Delta_{0 \rightarrow 100 \text{days, Exposed}}$	0	-0.01 (-0.05, 0.03)	0.07 (0.03, 0.11)
Non-Hispanic Black	$\text{Time}_{0, \text{Cohort}}$	29.5	29.4	29.2
	$\text{Time}_{0, \text{Cohort}} - \text{Time}_{0, \text{Exposed}}$	0	-0.12 (-0.24, -0.01)	-0.33 (-0.48, -0.19)
	$\Delta_{0 \rightarrow 100 \text{days}}$	0.01 (-0.05, 0.07)	-0.03 (-0.06, -0.01)	0.05 (0.01, 0.08)
	$\Delta_{0 \rightarrow 100 \text{days, Cohort}} - \Delta_{0 \rightarrow 100 \text{days, Exposed}}$	0	-0.04 (-0.11, 0.02)	0.04 (-0.03, 0.1)
Not Hospitalized	$\text{Time}_{0, \text{Cohort}}$	29.8	29.8	29.5
	$\text{Time}_{0, \text{Cohort}} - \text{Time}_{0, \text{Exposed}}$	0	-0.02 (-0.08, 0.03)	-0.26 (-0.32, -0.19)
	$\Delta_{0 \rightarrow 100 \text{days}}$	0 (-0.03, 0.02)	-0.04 (-0.05, -0.03)	0.03 (0.01, 0.04)
	$\Delta_{0 \rightarrow 100 \text{days, Cohort}} - \Delta_{0 \rightarrow 100 \text{days, Exposed}}$	0	-0.04 (-0.07, -0.01)	0.03 (0, 0.06)
Hospitalized	$\text{Time}_{0, \text{Cohort}}$	29.2	29.1	29.1
	$\text{Time}_{0, \text{Cohort}} - \text{Time}_{0, \text{Exposed}}$	0	-0.13 (-0.24, -0.01)	-0.07 (-0.29, 0.15)
	$\Delta_{0 \rightarrow 100 \text{days}}$	0.01 (-0.05, 0.08)	-0.02 (-0.04, 0.01)	0.05 (-0.02, 0.12)
	$\Delta_{0 \rightarrow 100 \text{days, Cohort}} - \Delta_{0 \rightarrow 100 \text{days, Exposed}}$	0	-0.03 (-0.1, 0.04)	0.04 (-0.06, 0.13)

Confidence intervals unavailable for predicted values at T=0 for all cohorts.

Supplementary Figure 1. Cohort selection




Supplementary Figure 2. Flowchart of analytic sample selection



		Exposed	Unexposed	Historical
BMI	Unique patients	32,384	127,142	35,266
	Observations in follow-up	188,060	809,483	233,088

Supplementary Figure 3. Statistical analysis approach



Supplementary Methods. Detailed statistical methods

Step 1. Investigator specified covariates

We extracted investigator specified covariates from the lookback period for each patient in the study sample (**Table SM1**). We imputed values as ‘no’ for those medications, comorbidities and encounter types if they were not present in the electronic health record for that patient. For other classes of nominal variables (health system, insurance category) we imputed missing values with the mode of the dataset. For continuous laboratory and anthropometry variables, missing data were single-imputed as the mean of available values across combinations of age, sex, race-ethnicity, health system, and exposure cohort..

Table SM1. Investigator-specified covariates prior to outcome measurement

Demographics	At or closest to index date	Within 1 year of index date	Within 2 years of index date
Sex	Age and calendar month of admission	Smoking status (yes/no) ^c	Comorbidities using grouped ICD10-CM codes (yes/no: 6 variables: obesity, cardiovascular, cerebrovascular, hypertension, pulmonary, hyperlipidemia) ^a
Race/ethnicity (4 categories: NH White, NH Black, Hispanic, NH Other)	Health system (8 categories) ^b	Medication classes (yes/no: 5 variables; antidepressants, antipsychotics, antihypertensives, statins, immune suppressants) ^a	
	Primary and secondary insurance type (7 categories) ^b	Laboratory parameters (actual; HbA1c, Glucose, ALT, AST, SCreatinine, HDL, LDL) ^c	
	Hospitalization status (yes/no) and counts of encounters (hospitalization, not hospitalization) ^a	Anthropometry (actual; BMI, height, SBP) ^c	
	Hyperglycemia in blood glucose values between index date and origin date ^c	Times encounters were observed (counts; Hospitalization, Telehealth, Outpatient) ^a	
		Times laboratory parameters were assessed (counts; Glucose, HDL, LDL, SCreatinine, ALT, AST, HbA1c, any lab visit) ^a	
<p>a Missing values set to ‘no’ ~ 0 b Missing values imputed using mode c Missing values imputed using group mean (sex, race/ethnicity, age, health system)</p>			

Step 2. Empirically identified covariates

Recommendations for high dimensional propensity scores (Rassen 2023 *Pharmacoepidemiol Drug Saf.*) suggest categorizing available data dimensions to identify covariates for score prediction in two steps: identify the top 200 covariates with highest prevalence and create indicator variables for each based on intensity (frequency: at least once, sporadic, frequent) prior to exposure relative to others in analytic sample. The recommendation is that these covariates are then prioritized (ranked) based on potential impact of confounding using quantities such as the Bross formula (Haris 2021 *arXiv*), and then selected for inclusion in the propensity model.

Identification of variable associated with the outcome and exposure, and not exposure alone is important to minimize instrumental variable bias (hdPS variables D in **Figure SM1**). Instrumental variable bias could increase bias and variance (decrease precision) of the estimated associations after propensity score adjustment. We aimed to minimize the inclusion of instrumental variables by performing variable selection prior to propensity score estimation.

Figure SM1. Causal diagram for variable selection from empirically identified covariates




Figure SM 1 Causal diagram for variable selection from empirically identified covariates

Given the nature of outcomes in this study (longitudinal, irregular time intervals between measurements), we used linear mixed models fit using maximum likelihood for variable selection. We assessed the statistical significance of the model fit of each covariate indicator variable using likelihood ratio tests ($df = 1$), in addition to a model that includes only the time from origin date (index date + 30 days) as a continuous variable. We applied a false discovery rate adjusted p-value cutoff of 0.05 (Benjamini 1995 *J Royal Stat. Soc.*) to identify variables associated with the longitudinal outcome (**Table SM2**).

Table SM2. Empirically identified covariates for the main analysis

Data Dimension	Variables Identified	Variables selected for categorization	HD covariates associated with longitudinal outcome #	HD covariates with at least 100 observations per exposure group	Additional variables associated with outcome availability during follow-up[^]
Inpatient diagnoses	537	200	387	6	0 out of 66
Outpatient diagnoses	537	200	512	438	64 out of 71
Inpatient procedures	1951	200	451	302	38 out of 142
Outpatient procedures	1951	200	499	409	64 out of 90
Prescribing	89	89	223	199	35 out of 36
Labs	877	200	312	231	54 out of 107
Total	5942	1089	2341	1585	253 out of 512

hdPS variables A, B. ^ hdPS variables C

Step 3. Propensity score models for exposure membership

We restricted further analysis to high dimensional covariates with at least 100 observations within each exposure group. We followed a three-step process to estimate propensity scores (PS) for the study sample (n = 249,743). The objective is to develop a generalizable multiclass prediction model for PS that balances all pre-treatment covariates across the exposure groups (Exposed, Unexposed, Historical Control).

3.1 Model selection: We split the dataset (70/30) into training and test sets, stratified by exposure group. We used five-fold cross-validation for model selection with the highest area under the receiver operating characteristic curve (the macro-weighted AUC).

We used random forests algorithm (Brieman 2001 *Machine Learning*) fit using the ranger package (v 0.14.1) under four combinations of number of trees (number: 1000, 2000), minimum node size (size: 10, 25). The default number of variables sampled per split was floor(sqrt(number of columns)). Although overfitting PS models was identified as “not necessarily harmful” (Rosenbaum 1987 *JASA*), some authors suggest that this may lead to inflation of variance of estimates of association when applying them for confounding adjustment (Schuster 2016 *J Clin Epidemiol*). We included all investigator specified covariates and only those empirically identified covariates associated with any of the longitudinal outcomes. We used random forests with penalization given the algorithm inherently performs variable selection and incorporates statistical interactions between variables. Since socio-demographic characteristics were included in the prediction model, we did not fit separate prediction models when assessing subgroup differences.

The similar performance in the training and test sets for the propensity score models suggest that the model did not overfit. We assume that any positivity violation that the model may have encountered during model fitting were random, and not structural (Hernan and Robins 2023 *What If* Chapter 12).

3.2 Model fit: We fit the complete dataset using the most parsimonious set of parameters to predict the PS of membership in the exposure group which each person belongs to. We trimmed extreme propensity score weights to 2.5th percentile (low) and 97.5th percentile (high). We used the inverse of the propensity score as the inverse probability of treatment weight (IPTW).

3.3 Stabilized inverse probability of treatment weights (SIPTW): We multiplied the inverse probability of treatment weights with the prevalence of each outcome to obtain stabilized IPTW (Austin 2015 *Stat in Med*), which is beneficial for those with extreme IPTW (very low or very high probability of membership in an exposure group).

3.4 Covariate balance: We assessed covariate balance by plotting the distribution of the probability of membership in different cohorts.




Figure SM 2 Distribution of probability of membership in different cohorts

We further examined population standardized bias for investigator specified covariates after weighting by SIPTW (McCaffrey 2013 *Stat in Med*). Population standardized bias assesses balance if the weighted mean/proportion of each exposure group differs relative to the pooled, unweighted mean/proportion of the study sample.




Figure SM 3 Distribution of stabilized inverse probability weights after trimming

Step 4. Propensity score models for follow-up

We split the dataset (70/30) into training and test sets, stratified by exposure group among patients with ($n = 194,792$ out of 249,743) and without BMI in the follow-up period. In the set of predictors, we additionally included the exposure group and variables associated with the follow-up status for that outcome, but not with the outcome trajectory for any outcome. We followed similar parameter tuning and performance metrics as Step 3.

Given the non-overlap in stabilized inverse probability of treatment weights, we additionally adjusted for all imbalanced investigator-specified covariates in the final outcome regression model.